Name: Harald P. Hoensch

Position:

• Retired Chief physician of Gastroenterology
• Specialist of Internal Medicine and Gastroenterology
• Specialist of GI-oncology
• Private physician of Internal Medicine and Gastroenterology
• AGAF (Fellow of the American Gastroenterological Association)
• Retired since 2007

Title: Prof. Dr. med.

E-mail: h.p.hoensch@t-online.de

Address:

Recent Papers (first author):

• Regulation of the intestinal immune system of flavonoids and its utility in chronic inflammatory bowel disease. World J. Gastroenterology 2018 February 28; 24(8): 877-881.
• The value of flavonoids for the human nutrition: short review and perspectives. Clinical Nutrition Experimental. 2015; 3: 8-14
• Neue Konzepte bei chronisch entzündlichen Darmkrankheiten. Praxis Magazin 9/2015
• Disparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas, World J Gastroenterol 2013; 19(36): 6020-6025;DOI:http://dx.doi.org/10.3748/wjg.v19.i36.6020.
• Poster Price, Deutsche Gesellschaft für Klinische Pharmakologie: Down regulation of inducible inflammatory genes of colon cancer cells, Dresden 2012.
• Emerging role of bioflavonoids in gastroenterology, World J Gastrointestinal Oncology 2011, 3(5): 71-74.
• Flavonoide zur Krebsprävention im Darm. MedKlin 2010; 105: 554-559.
• Poster Price Falk Workshop Mainz Germany September 17, 2008. Strategies of Cancer Prevention in Gastroenterology
• Flavonoide in der Prävention von Darmneoplasien. Prävention und Versorgungsforschung, Springer Medizin Verlag Heidelberg 2008; 691-704
• Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol. 2008, 14(4):2187-2193
• Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age. Current Medical Research and Opinion. 22, 1075-1084, 2006
• Potential Role of Flavonoids in the Prevention of Intestinal Neolasia, Int. J. of Gastrointestinal Cancer, vol. 35, no. 3, 187-196, 2005.
• Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system; GUT 2002, 50:235-240.
• Letter to the Editor (PostScript), RE: Influence of clinical factors, drug use, and food intake on the glutathione system; GUT 2003, 52:154-155.
• Hoensch HP, Weigmann B. Nutritional Health and Bioflavonoids. Recent Progress in Nutrition 2022; 2(3):12; https://www.lidsen.com/journals/rpn/rpn-02-03-017
• Pyrrolizidin-Alkaloide in der Nahrung: Der toxikologische Blick - Pyrrolizidin-Alkaloide und Grüne Tees, H.Hoensch und R.Zenger, Verdauungskrankheiten 38, Nr. 5/2020. S. 216-219

Current Research Activities:

• Clinical Trials.gov Identifier: NCT00609310 : Flavonoids to prevent recurrences in patients with resected colorectal cancer or colorectal adenomas (validation study)
• Flavonoid plasma levels in patients on oral flavonoid treatment (technical university Dresden Germany, department of clinical pharmacology)
• Glutathion-system in gut and liver, protective antioxidative, antitoxic enzymes to prevent neoplasia of the gut by induction with dietary flavonoids.
• Prof. Dr. Wolfgang Kruis, Evangelisches Krankenhaus Kalk, Köln, Germany: Flavonoid uptake in chronic inflammatory bowel disease
• Kölbel Krankenhaus, Köln-Kalk, Evangelisches Krankenhaus

Academic Activities:

• Collaboration with University of Erlangen, Germany, GI-department
• (postgraduate activities)
• Referee for "Carcinogenesis" and "Clinical Chemistry and Laboratory Medicine"
• Member of Editorial Board of World J Gastroenterol

Clinical Service:

• Full certification for complete training of Internal Medicine and Gastroenterology
• Consulting physician : Marienhospital Darmstadt Germany

Professional Activities:

• AGA Community
• DGVS

Cooperative Activities:

• Prof. Dr. Benno Weigmann, 1. Med. Klinik, Forschungscampus, Universität Erlangen, Germany

Memberships:

• American Gastroenterological Association (AGA)
• German Association of Digestive and Metabolic Diseases (DGVS)
• German Association of Internal Medicine
• Arbeitsgemeinschaft Präventive und Integrative Onkologie (PRIO) der Deutschen Krebsgesellschaft